Immunic (IMUX) Q2 2024 earnings summary

Executive summary

• Reported Q2 and H1 2024 financial and operational results, highlighting clinical progress in MS and GI programs, and upcoming milestones for lead assets.

• Advanced vidofludimus calcium in phase II (CALLIPER) for progressive MS and twin phase III (ENSURE) trials for relapsing MS, with key data readouts expected in the next 6-9 months.

• IMU-856 completed phase 1b in celiac disease, showing significant improvements, and is preparing for phase 2 pending additional financing or partnerships.

• Strengthened management with appointments of Jason Tardio as COO/President, Werner Gladdines as CDO, and Simona Skerjanec to the Board, all with significant industry experience.

• Hosted an in-person MS R&D Day and published extended phase II EMPHASIS trial data in a leading neurology journal.

Financial highlights

• Ended Q2 2024 with $79.7M in cash and cash equivalents, expected to fund operations into Q3 2025.

• R&D expenses for Q2 2024 were $18.3M, down from $21.2M in Q2 2023, mainly due to reduced costs in IMU-856 and deprioritization of izumerogant.

• G&A expenses for Q2 2024 were $4.5M, up from $3.8M in Q2 2023, primarily due to higher personnel and legal costs.

• Net loss for Q2 2024 was $21.4M ($0.21/share), compared to $24.0M ($0.54/share) in Q2 2023; net loss for H1 2024 was $51.0M ($0.51/share) vs. $49.3M ($1.12/share) in H1 2023.

• Operating expenses for Q2 2024 were $22.8M, down from $25.0M in Q2 2023.

Outlook and guidance

• Top-line data from phase II CALLIPER trial in progressive MS expected in April 2025.

• Interim futility analysis for phase III ENSURE program in relapsing MS expected in Q4 2024; first ENSURE trial completion targeted for Q2 2026, second in H2 2026.

• Preparing for phase II clinical testing of IMU-856 in celiac disease and other GI disorders, contingent on additional financing or partnerships.

• Current cash is insufficient to fund operations for 12 months from the financial statement issuance date; additional capital will be required.

• The company expects continued significant expenses and operating losses as it advances clinical programs and expands personnel.